The company describes EndoArt as the world’s first synthetic endothelial layer for the treatment of chronic corneal edema.

NPR's Steve Inskeep asks FDA Commissioner Marty Makary about recent controversies around the COVID and Hepatitis B vaccines, and the lack of trust in the government's medical advice.

Taking drops of a medical dye is trending in wellness and biohacking circles. Some influencers claim it boosts longevity and ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

A yearlong pattern of intense disruption followed by little improvement played out across nearly every major healthcare ...

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...

Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial.

Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Discover why monk fruit sweetener might be the healthier alternative to regular sugar. Understand the nutritional profiles, ...

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...